Momenta Must Face Clot Drug Antitrust Row, 1st Circ. Told

Law360, New York (November 1, 2016, 3:23 PM EDT) -- Misconduct by Momenta before a standard-setting organization that unknowingly led the group to create a standard for a blood-clot drug that requires the use of a company patent should not allow the generics maker to subsequently receive immunity from antitrust claims, generic rival Amphastar told the First Circuit on Monday.

The District of Massachusetts erred by holding in July that the so-called Noerr-Pennington doctrine allowed Momenta Pharmaceuticals Inc. and co-defendant Sandoz Inc. to escape the antitrust claims brought by Amphastar Pharmaceuticals Inc., which alleged that Momenta violated the Sherman Act by allegedly suppressing competition of sales of a generic blood clot...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!